Dynavax Names Denise M. Gilbert to Board of Directors
BERKELEY, Calif., March 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that Denise M. Gilbert, Ph.D., has joined its Board of Directors. Dr. Gilbert will also serve as chair of the Board's Audit Committee. With Dr. Gilbert's addition, Dynavax's Board of Directors increased to seven members.
Dr. Gilbert is currently an independent consultant and strategic advisor to life science companies. Previously, she served as Chief Executive Officer of Entigen Corporation, a private life science information technology company. In addition, Dr. Gilbert has served as Chief Financial Officer of two public companies, Incyte Pharmaceuticals Inc. and Affymax NV. From 1986 through 1993 Dr. Gilbert was a senior biotechnology analyst at Smith Barney Harris & Upham and Montgomery Securities. Dr. Gilbert currently serves as a Director of Connetics Corporation, a public specialty pharmaceutical company, as well as a Director of a private life science company. Dr. Gilbert holds a B.A. from Cornell University and a Ph.D. in Cell and Developmental Biology from Harvard University.
"Denise's experience as a biotech executive and Wall Street analyst complements the talent already present on our Board," said Dr. Dino Dina, Dynavax's president and chief executive officer. "We look forward to her contributions to help Dynavax meet the demands of the public markets and enhance the value of its shareholders' investment in the company."
About Dynavax
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Note: This press release contains "forward looking statements" within the meaning of the federal securities laws. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Dynavax undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release except as required by law.
SOURCE Dynavax Technologies Corporation